Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brainstorm Cell Therapeutics ( (BCLI) ) has issued an announcement.
Brainstorm Cell Therapeutics, Inc. has released a presentation highlighting its autologous cell therapy platform, NurOwn®, for neurological disorders such as ALS and MS. The company is progressing towards a Phase 3b trial, with finalized clinical site agreements and manufacturing capabilities in place. NurOwn® has shown promise in prior trials, demonstrating improvements in patients and robust biomarker data supporting its mechanism of action. The presentation also outlines the company’s experienced team and strategic milestones, including first patient enrollment expected by December 2024.
See more insights into BCLI stock on TipRanks’ Stock Analysis page.